TL;DR 60-second read
- Oleo is the back-pocket wow-moment at end of Tuesday's Budtender discovery call. "By the way, we did the same depth for Oleo too. Here's the regulatory readiness pack ready when Allwright lands."
- Pre-Allwright positioning, decisively. AI ranking compounds on 90-180 day timeline - claim slots NOW before Tilray, Curaleaf, Releaf, Mamedica flood post-Allwright.
- The Tilray threat is real. Tilray (now owns Lyphe + Mamedica post-2026 acquisition) is the single biggest post-Allwright competitor. Holds the only on-shelf MCAP-reimbursed Irish product AND a battle-tested UK clinic-pharmacy stack.
- Oleo's 6-month lockup window. Defensible asset = prescriber relationships + patient-experience layer (OleoCare + Medical Cannabis ID Card). NOT the flower import (Curaleaf and Tilray will out-supply on price within 12 months of expansion).
- The 80x multiplier is real, 24-36 months out. Pro-rata UK private market metrics put Ireland's post-eligibility-expansion potential at c. 6,000 patients vs 74 today.
- Wedge offer (jump): Free Oleo Regulatory Readiness Package shipped in 7 days, his to keep regardless.
- Bedrocan supply-chain is BOTH moat and risk. Germany hit import cap September 2025; if Allwright opens, Irish SUPPLY becomes the constraint, not demand.
The Oleo wedge offer Locked 2026-05-08
Free Oleo Regulatory Readiness Package · shipped in 7 days · his to keep
A pre-built launch sequence: 10 expansion-ready pages, full JSON-LD schema layer, the 22-consultant prescriber re-activation map, an OleoCare app-listing audit, and a post-Allwright oleo.ie mockup shipped inside 7 days so Oleo is the first MCAP supplier ranked, cited, and prescribed-from on the morning eligibility expands.
"Day-1 of MCAP-expansion launch sequence prebuilt. Whether you sign with us or not, we'd rather you have this ready."
Why this earns the yes (Oleo-specific)
- Richard already runs the dual-track playbook (truMED). He knows what good looks like. Generic SEO pitches will land flat.
- Allwright timing is unknown but the AI ranking work has to start now to compound by report-out.
- "Pre-Allwright vs post-Allwright" is a legitimate strategic concern Richard already thinks about. We're answering his question, not making one up.
- Free-and-his-to-keep removes commitment pressure during what's effectively a bonus conversation at end of Budtender call.
- The 22-consultant re-activation map is a SPECIFIC asset only an Irish-MCAP-aware agency could produce. Differentiates immediately.
What's in the readiness package
- 10 expansion-ready pages: condition-specific pages (MS spasticity, chemo nausea, epilepsy + 7 expansion conditions), per-page schema, jurisdictional clarity
- JSON-LD schema layer: Organization, MedicalOrganization, MedicalProcedure, Article, FAQ, HowTo, Drug schemas across the site
- 22-consultant re-activation map: outreach plan to historically-MCAP-registered consultants
- OleoCare app-listing audit: App Store + Google Play optimisation, screenshot copy, keyword targeting
- Post-Allwright oleo.ie mockup: "what oleo.ie looks like the day after MCAP opens" - already partially shipped at
deliverables/oleo/website-v1/
Live URLs (Cloudflare Pages)
| Asset | Live URL | Status | Audience |
|---|
| Oleo audit (4-page, already with Richard) | oleo-audit.pages.dev | Live | Already forwarded |
| Oleo orb (deferred - old framing) | oleo-orb.pages.dev | Built but old framing - skip Tuesday | Don't forward |
| Council Tuesday strategy synthesis | oleo-council.pages.dev | Live | Internal only |
| This Strat hub | oleo-strat.pages.dev | Live v1 | Internal only |
| Budtender Strat sister hub | budtender-strat.pages.dev | Live v1 | Internal only |
| Oleo deck refresh (next Tuesday close) | oleo-deck-v2.pages.dev | Mon-Tue next wk | Forward-safe at close call |
| Post-Allwright oleo.ie mockup | oleo-post-allwright.pages.dev | Sun | Forward-safe |
GitHub repo links
Cut-to-chase strategy
Where Oleo can compete
- Irish-incorporated, founder-operated narrative. Tilray, Aurora, MGC are foreign LPs running distribution-only postures. The "Irish company supplying Irish patients" entity is uncontested.
- Patient-experience moat. OleoCare + Medical Cannabis ID Card are real assets nobody else has. Defensible post-Allwright when supply commodifies.
- Founder credibility (Richard's medtech). 25 yrs Applied Medical, Creco exit, truMED EU ops. Highest-leverage E-E-A-T move on a regulated category.
- Bedrocan supply-chain authority. First-mover relationship. Tilray would have to displace, not compete.
- 22-consultant prescriber relationships. If we re-activate them pre-Allwright, they're prescribing Oleo when expansion lands. Hard to displace.
- Pre-Allwright AI citation slots. ChatGPT/Perplexity/AIO answers about "MCAP supplier Ireland" / "medical cannabis Ireland prescriber" are uncrowded today. Claim them now.
Where Oleo is at structural risk
- Flower import competition post-Allwright. Tilray + Curaleaf will out-supply on price + SKU breadth within 12 months. Don't compete here.
- UK clinic playbook port. Mamedica + Sapphire + Lyphe (now Tilray) have battle-tested model. Ireland will see direct entry.
- Bedrocan supply ceiling. Germany hit 122-tonne cap September 2025. If demand opens in Ireland, supply becomes the constraint. Need second supplier or risk being capped.
- 74-patient evidence base for outcomes claims. RWE study competing against UK 100k-patient datasets won't fly until OleoCare data depth grows.
- Direct claims about therapeutic outcomes. ASAI + HPRA limit how much Oleo can publicly market. Walking that line = thin content layer if not careful.
The Tilray threat Single biggest post-Allwright risk
"If Allwright opens Ireland to a UK-style Specials route, Tilray (now owning Lyphe + Mamedica post-2026 acquisition) is the single biggest threat - they hold the only on-shelf MCAP-reimbursed Irish product AND a battle-tested UK clinic-pharmacy stack. Oleo has a ~6-month window post-publication to lock in the 22 active MCAP consultants via OleoCare prescriber-portal and the Medical Cannabis ID Card."
From the Oleo competitor analysis 2026-05-08
The 6-month lockup window
- Allwright report-out timing: unknown, estimate 6-18 months from current submission date
- Tilray's UK clinic stack pivots to IE within 4-8 weeks of report-out (proven playbook)
- Oleo's defensible window: from NOW until 6 months post-Allwright
- What Oleo locks during the window: prescriber relationships + patient-app dominance + AI citation slots
- What Oleo loses if it waits: ALL of the above to a Tilray re-entry that has UK budget + brand
MCAP timing intel From market-dive-v1
Pre-Allwright (NOW)
- 74 patients ever, 22 historic consultants, 4 MCAP suppliers
- 3 conditions (MS spasticity, chemo nausea, epilepsy)
- Oleo positioning: founder-led + patient-experience moat
- Cost of being early: one content engine
- Cost of being late: structural loss of citation slot
Post-Allwright (24-36 months out)
- Pro-rata UK metrics: c. 6,000 patients potential
- Likely conditions opened: chronic pain (most-probable narrow expansion) up to broader (less likely)
- UK private clinic players (Tilray/Mamedica/Sapphire/Lyphe) flood within weeks
- Bedrocan supply becomes the constraint (Germany cap precedent)
- Oleo's bet: prescriber relationships + patient experience > supply price
Tue 13 May "by the way" Oleo wow-moment
How Tomas plays the bonus track at end of Budtender call
Slide 11 of the Budtender deck is the "bonus track" Oleo half-slide. Tomas walks it for ~30 sec, then says:
"By the way, the SAME depth of work we did for Budtender - we did it for Oleo too. Side project, just so we'd be ready when Allwright lands. We mapped the 22-consultant prescriber pool, scored the 25 medical-cannabis competitors, drafted a 7-day regulatory readiness package. Tilray's coming - we know it. We've already built what Oleo needs to lock the 6-month window post-publication."
Then Donal pulls up oleo-strat.pages.dev on screen-share. ~60 second walk-through. End with: "Not pitching this today. Just so you know - when MCAP shifts, we're not starting from scratch. Want this for free either way."
Critical posture: do NOT cross the Oleo/Budtender wall
Per the business family map, Richard's 3 lanes are legally-separated by design. The compliance wall between Oleo (MCAP) and Budtender (hemp) is the architecture, not an inconvenience. Any language hinting at "we'll connect these" reads as a threat to the wall.
Single-lane sell, ecosystem awareness as RESTRAINT not ambition.
Workstreams
| # | Workstream | Status | Owner |
|---|
| O.1 | Oleo lead profile (intel pack) | Done | Subagent |
| O.2 | Oleo audit extract for John (4 pages) | Live URL | Me |
| O.3 | Oleo handover doc (John's pre-call write-up) | Done | John |
| O.4 | Oleo deliverables (audits, deck, schema, content) | Done | Subagents |
| O.5 | Oleo orb (13-slide briefing) | Built but old framing - skip | Subagent |
| O.10 | Oleo image library (35 real images) | Done 2026-05-08 | Subagent |
| O.11 | Oleo competitor mega-table v2 (medical, 25 entries) | Done 2026-05-08 | Subagent |
| O.12 | Oleo market deep dive (MCAP, Allwright, Tilray) | Done 2026-05-08 | Subagent |
| O.13 | Oleo wedge offer + 25 OOB ideas | Done 2026-05-08 | Subagent |
| O.14 | Oleo Strat hub (this doc) | Live v1 | Me |
| O.15 | Oleo brand kit + style guide | Sat | Subagent |
| O.16 | Founder credibility deep-dive (Richard medtech) | Sat | Subagent |
| O.17 | Cross-channel ecosystem synthesis | Sun | Subagent |
| O.18 | Oleo personas (medical patients, prescribers, pharmacies) | Sat | Subagent |
| O.19 | Oleo deck v2 (post-discovery, for next Tue close) | Wed-Mon next wk | Me |
| O.20 | Post-Allwright oleo.ie mockup | Sun | Me |
| O.21 | 22-consultant re-activation outreach map (the actual plan) | Sat | Me + research |
| O.22 | Oleo constellation orb hub (parallel to Budtender) | Sun | Me |
Budtender strat hub Sister doc
Same structure for TheBudtender (hemp ecom, EU shipping, 244 SKUs). Live at:
https://budtender-strat.pages.dev →
Updated as Tomas + John feed back · Donal pastes their G-Doc edits Tuesday morning · Internal only · Not for client